

**Eylea (afibercept)  
Effective 01/01/2021**

<b>Plan</b>	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit (NLX)		
<b>Specialty Limitations</b>	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
<b>Contact Information</b>	<b>Specialty Medications</b>		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	<b>Non-Specialty Medications</b>		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	<b>Medical Specialty Medications (NLX)</b>		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
<b>Exceptions</b>	N/A		

### Overview

Aflibercept is a recombinant fusion protein that acts as a decoy receptor for vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PLGF). Aflibercept binds to VEGF-A and PLGF and inhibits binding and activating of endothelial cell receptors, thereby suppressing neovascularization and slowing vision loss.

### Coverage Guidelines

#### Ophthalmic disorders

Authorization of 24 months may be granted for treatment of the following retinal disorders:

1. Diabetic macular edema
2. Neovascular (wet) age-related macular degeneration
3. Macular edema following retinal vein occlusion
4. Diabetic retinopathy

#### Continuation of Therapy

All members requesting authorization for continuation of therapy must meet all initial authorization criteria.

#### Limitations

Approvals for all diagnoses will be granted for 24 months

#### References

1. Eylea [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals; May 2019.
2. American Academy of Ophthalmology Retinal/Vitreous Panel. Preferred Practice Pattern® Guidelines. Age-Related Macular Degeneration. San Francisco, CA: American Academy of Ophthalmology; 2019. 399 Revolution Drive, Suite 810, Somerville, MA 02145 | allwayshealthpartners.org



Ophthalmology; 2015. Available at: <https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp-2015>

3. American Academy of Ophthalmology Retinal/Vitreous Panel. Preferred Practice Pattern® Guidelines. Diabetic Retinopathy. San Francisco, CA: American Academy of Ophthalmology; 2017. Available at: <https://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp-updated-2017>
4. American Academy of Ophthalmology Retinal/Vitreous Panel. Preferred Practice Pattern® Guidelines. Retinal Vein Occlusions. San Francisco, CA: American Academy of Ophthalmology; 2015. Available at: <https://www.aao.org/preferred-practice-pattern/retinal-vein-occlusions-ppp-2015>

### **Review History**

11/18/2020 – Transitioned from SGM to Custom Criteria; separated out MH vs. Comm/Exch criteria.

### **Disclaimer**

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.